Founder led companies can offer a different kind of anchor when inflation trends are mixed, central banks keep investors guessing on rates, and energy and credit costs pull market sentiment in different directions. These leaders often have their own capital, reputation, and long term legacy tied to every decision. That can focus attention on disciplined capital allocation, resilience through policy shifts, and careful use of debt. This article looks at why a founder mindset can matter in this backdrop and then walks through 3 notable stocks from our Founder-Led Companies screener to help you sharpen your watchlist.
Lightspeed Commerce (TSX:LSPD)
Overview: Lightspeed Commerce provides a cloud-based commerce platform that helps retailers, restaurants, and other businesses run their front of house and back office in one place, from point of sale and inventory to loyalty, payments, and eCommerce. It also sells payments and capital products plus hardware like tablets and scanners, tying software, transactions, and financing together for single and multi location operators.
Market Cap: CA$2.06b
Lightspeed Commerce sits at the intersection of software and payments, with recurring subscription and transaction revenue tied to the ongoing shift toward cloud systems, omnichannel retail, and integrated payments. The business is still loss making, yet recent results show a much smaller net loss alongside revenue guidance above $1.2b for full year 2027. Buybacks also indicate management is willing to return capital. At the same time, reliance on higher risk external funding, ongoing losses, and tough competition from Shopify, Toast, and others keep execution risk high. For investors who can accept those trade offs, the combination of solid top line growth forecasts, a discounted P/S multiple, and founder led discipline makes the deeper story worth a closer look.
Lightspeed Commerce’s shrinking losses, upcoming revenue targets and buybacks raise a clear question: Is the market mispricing this founder led shift toward scale? Get the full picture in the 3 key rewards and 1 important warning sign
Corcept Therapeutics (CORT)
Overview: Corcept Therapeutics is a biopharmaceutical company that develops and sells drugs that modulate the hormone cortisol to treat serious endocrine, cancer, metabolic, and neurologic conditions. Its commercial product Korlym targets high cortisol in adults with Cushing’s syndrome, while a pipeline of selective cortisol modulators such as relacorilant, miricorilant, nenocorilant, and dazucorilant aims to extend this approach into obesity related liver disease, ovarian cancer, and Lou Gehrig’s disease.
Market Cap: US$10.0b
Corcept Therapeutics may attract attention from investors because it already has a commercial product in Korlym while at the same time advancing a broad pipeline of selective cortisol modulators toward key FDA decisions across endocrinology and oncology. Reported Q2 2026 results included record revenue and a guidance range of US$1.1b to US$1.2b, which was supported by the Lifyorli launch in platinum resistant ovarian cancer. The stock still faces concentration risk, as Korlym and its authorized generic are exposed to pricing and patent pressures. Analyst forecasts of earnings and revenue growth are accompanied by debate on valuation, insider selling, and legal outcomes. Corcept is a founder led business where execution on upcoming FDA milestones could be an important factor alongside the headline valuation multiples.
Corcept Therapeutics sits at the crossroads of record revenue, new products and a packed FDA calendar, yet the real story may be hiding in how risks and rewards line up from here. See how the 1 key reward and 1 important warning sign
Klaviyo (KVYO)
Overview: Klaviyo provides a cloud based B2C CRM platform that helps online brands pull customer data, marketing, service, messaging, reviews, and analytics into one system, then use AI tools like Marketing Agent and Customer Agent to automate campaigns and support across email, SMS, WhatsApp, and social channels.
Operations: Klaviyo generates about US$1.31b in revenue from Internet Software, with around US$778.65m from the United States and the rest spread across Europe, the Middle East, Africa, Asia Pacific, and other Americas markets.
Market Cap: US$5.80b
Klaviyo is attracting attention because it sits at the intersection of AI, first party data rules, and B2C e commerce, with products like Composer AI, Klaviyo Social, and Customer Hub widening its reach beyond email into full CRM and support. Revenue guidance for 2026 of roughly US$1.5b, fresh index inclusion in several Russell benchmarks, and active buybacks indicate a management team focused on scale and capital discipline. At the same time, the stock is still working through unprofitability, volatile SMB exposure, tough competition from larger software groups, and questions about how quickly new AI tools will translate into earnings. For founder led investors, the open question is whether today’s risk and price properly reflect that bigger opportunity.
Klaviyo’s push to scale AI driven customer tools and expand beyond email raises a simple question: Are investors fully pricing in where this could lead? See how the analyst forecasts for Klaviyo lines up with the key risk that could change the story.
The three founder led stocks in this article are only a starting point, since the full screen flags 1,454 more companies with equally compelling founder stories in the Founder-Led Companies screener. Identify and analyze the exact catalysts, capital discipline markers, and leadership narratives that matter to you, so you can focus on the founder led companies that best match your highest conviction ideas.
Take Control of Your Investment Journey
If Corcept Therapeutics or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.
Curious About Exploring High Conviction Alternatives
Fresh ideas can move fast. Some are building quiet momentum, others are dropping into attractive ranges under the radar for now. Scan these breakouts before the crowd and act now.
- Spot strong cash generators before momentum really starts by scanning a curated 8 high quality undervalued stocks that still trade below what their fundamentals might justify, while it matters.
- Ride structural shifts in automation and efficiency by reviewing a focused set of 34 robotics and automation stocks that could benefit as spending on smart machines gains traction.
- Track resilient balance sheets while pessimism is still priced in by checking a filtered list of solid balance sheet and fundamentals (11 results) that highlights durable financial strength, before sentiment flips.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com